Xiangyu Medical(688626) Guohai Securities·2025-05-01 06:28Investment Rating - The report assigns a "Buy" rating for Xiangyu Medical (688626) as it initiates coverage [1][7]. Core Insights - Xiangyu Medical is focusing on the development of brain-machine interfaces and rehabilitation robots, with revenue stabilizing and poised for growth [1]. - The company reported a slight decline in revenue for 2024 but showed signs of recovery in the last two quarters, with a 10% increase in Q1 2025 [4][6]. - Significant investment in R&D, with a 42% increase in 2024, indicates a commitment to maintaining technological leadership in the rehabilitation industry [6][7]. Financial Performance Summary - In 2024, the company achieved operating revenue of 744 million yuan, a decrease of 0.17% year-on-year, and a net profit of 103 million yuan, down 55% [4][6]. - For Q1 2025, revenue was 186 million yuan, reflecting a 10% increase, while net profit was 23 million yuan, a decrease of 41% [4][6]. - Revenue projections for 2025-2027 are 846 million yuan, 982 million yuan, and 1.141 billion yuan, with expected growth rates of 14%, 16%, and 16% respectively [6][8]. Profitability and Valuation Metrics - The forecasted net profits for 2025-2027 are 156 million yuan, 199 million yuan, and 255 million yuan, with growth rates of 52%, 27%, and 28% respectively [7][8]. - The projected P/E ratios for the same period are 39, 31, and 24 [7][8]. - The company maintains a strong gross margin, with 67.83% in 2024, although it is expected to slightly decline in the following years [6][9].